Faeth Therapeutics Raises $25M to Advance PIKTOR Therapy After 80% Response Rate in Endometrial Cancer
核心洞察
Faeth Therapeutics (搜索) secured $25 million in strategic funding led by S2G Ventures (搜索), bringing total capital raised to $92 million to advance its metabolism-based cancer therapies.
The company's PIKTOR (搜索) regimen achieved an 80% overall response rate and 11-month median progression-free survival in endometrial cancer (搜索) patients, significantly outperforming historical chemotherapy outcomes.
The Gynecologic Oncology Group Foundation (搜索) has initiated a Phase 2 trial based on these promising results, with full data readout expected in Q3 2026.
Faeth Therapeutics (搜索), a clinical-stage biotechnology company developing metabolism-based cancer therapies, announced a $25 million strategic financing round to advance its lead PIKTOR (搜索) program following breakthrough clinical results in endometrial cancer (搜索). The funding, led by S2G Ventures (搜索) with participation from existing and new investors, brings the company's total capital raised to $92 million.
Strong Clinical Results Drive Phase 2 Advancement
The financing follows compelling data from Faeth's Phase 1b study of the PIKTOR (搜索) regimen—a combination of serabelisib, sapanisertib, and paclitaxel—which demonstrated an 80% overall response rate in endometrial cancer (搜索) patients. The treatment achieved a median progression-free survival of 11 months, representing a dramatic improvement over the historical 3-4 months seen with chemotherapy alone.
Based on these results, the Gynecologic Oncology Group (GOG) Foundation, one of the premier U.S. clinical trial networks, has initiated a Phase 2 trial (GOG-3111; NCT06463028) that is now enrolling patients. The study includes a predefined substudy testing whether protocolized insulin control through precision nutrition enhances clinical outcomes under trial conditions.
Multi-Node Pathway Inhibition Strategy
Faeth's approach addresses a critical limitation in current cancer therapeutics by targeting the PI3K (搜索)/AKT (搜索)/mTOR (搜索) signaling axis, one of the most frequently altered pathways across solid tumors including endometrial, breast, lung, and ovarian cancers. Unlike conventional single-node inhibitors that often fail due to feedback reactivation and pathway mutations, Faeth employs selective multi-node inhibition at PI3K⍺, mTORC1 (搜索), and mTORC2 (搜索) while controlling the nutrient supply that tumors depend on.
"We've achieved the optimal balance in PI3K (搜索) pathway inhibition, comprehensive enough to prevent resistance, selective enough to avoid immunosuppression," said Anand Parikh, CEO of Faeth Therapeutics (搜索). "The 80% response rate, 11-month progression-free survival, initiation of a trial by the GOG Foundation, and recognition as a late-breaking oral presentation at ESMO show that Faeth is executing as a clinical-stage company positioned to expand across the solid tumors where PI3K alterations drive disease."
In preclinical models, this multi-node approach achieved more complete pathway shutdown than single-agent inhibition. Multi-node inhibition of the PI3K (搜索)/AKT (搜索)/mTOR (搜索) pathway has already shown clinical benefit in Phase 3 studies, confirming the value of pathway-level control in both mutant and wild-type tumors.
MetabOS Platform Expansion
The funding will expand throughput for Faeth's MetabOS™ platform, an AI-driven system that integrates genomic, gene expression, and tumor microenvironment data to identify metabolic dependencies and exploit them clinically. The platform recognizes that tumors have significantly elevated metabolic demands and require specific nutrients to survive, enabling Faeth to simulate and validate more regimens designed to address metabolic escape.
"If the cell is the unit of life, then metabolism is the first verb in its sentence," said Siddhartha Mukherjee, co-founder of Faeth Therapeutics (搜索). "Faeth is intervening where cellular decisions are made fastest: at the metabolic switches tumors rely on to adapt, long before mutations accumulate. That is why metabolism is emerging alongside the genome and immunogenicity as a therapeutic discipline."
Pipeline Expansion Beyond Oncology
The financing supports advancement of the Phase 2 endometrial cancer (搜索) program through a full data readout in Q3 2026, while also enabling expansion into additional indications. The funding will support a Phase 1 study in locally advanced rectal cancer (搜索) for Faeth's non-essential amino acid restricted program and initiation of the company's first non-oncology program in Hereditary Tyrosinemia Type 1 (搜索) (HT1), a rare pediatric metabolic disorder affecting 1 in 100,000 births.
For HT1, where toxic metabolites accumulate due to enzyme deficiency and current treatments still leave unmet medical needs despite preventing liver failure, Faeth is applying MetabOS to develop metabolic therapeutic approaches. IND-enabling studies are targeting Q4 2026 clinical entry, representing the first demonstration of MetabOS applied outside oncology.
Investment Perspective
"We're seeing validation of multi-node targeting in recent phase 3 studies," said Sanjeev Krishnan, Chief Investment Officer and Managing Director at S2G Ventures (搜索). "Insider participation in this financing reflects conviction in Faeth's progress, while new investors recognize metabolism as a category entering the clinic. Faeth's selective multi-node approach positions the company to capture value as metabolism becomes established as the 'fifth pillar' of cancer treatment."
The financing round included participation from existing investors Khosla Ventures (搜索), Future Ventures, Digitalis Ventures, KdT Ventures and Cantos, plus new investors B Capital Group, Avicella and THO Seed Fund. Clinical data from sapanisertib in combination with paclitaxel, one component of the PIKTOR (搜索) regimen, have been selected for a late-breaking oral presentation at the ESMO 2025 Congress.